Hepatitis C
Meeting the needs of millions still waiting for affordable treatment
Hepatitis C
Meeting the needs of millions still waiting for affordable treatment
We have developed a simple-to-use, affordable cure and tested new strategies to link patients to lifesaving treatment and care. We are also working to foster the political will needed for wide-scale roll-out of test-and-treat strategies together with allies in the Hepatitis C Partnership for Control and Treatment (Hepatitis C PACT).
Hepatitis C is caused by the blood-borne hepatitis C virus that can lead to chronic liver disease, cirrhosis, cancer, and, if not treated, death. Symptoms can take decades to develop and most people living with the disease do not know they are infected. As a result, hepatitis C is a silent epidemic.
Recent years have seen a revolution in medical innovation for hepatitis C, which can now be cured with just 8 to 24 weeks of safe, simple treatment. However, just 13% of people living with the disease worldwide have benefited. In many countries, high prices remain a major barrier for ‘test-and-treat’ strategies that have the potential to eliminate hepatitis C altogether.
‘Hepatitis C is a “silent epidemic” because people are unaware of their infection and go untreated for years.’
What we have achieved
We delivered a new treatment that is equal to the best hepatitis C drugs, at a fraction of the cost.
What we are doing for people living with hepatitis C
We are now working to help foster an enabling environment for improved availability of hepatitis C diagnostics and treatments in low- and middle-income countries and supporting innovative ‘test-and-treat’ programmes in several countries.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
